Movement Disorders

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the issues within the current system that prevent approvals for neurologic devices for rare diseases.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.

The chief scientific officer of the Parkinson’s Foundation offers his side of the debate on whether genetic testing for patients with Parkinson disease is under-utilized.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.

Researchers from the Mayo Clinic found a molecular target that can help assess potential treatments for spinocerebellar ataxia type 3, a disease which currently has no cure.

Here's what is coming soon to NeurologyLive.

The neurology resident at Magna Graecia University of Catanzaro also touched on how accurate early diagnoses can help hone clinical trial recruitment.

Neurology News Network for the week ending November 21, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 20, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Paul Fisher, MD, and Gerald Grant, MD, FACS.

The neurology resident at Magna Graecia University of Catanzaro discussed his team’s efforts to simplify differentiation between PSP and PD.

The chief scientific officer of the Parkinson’s Foundation detailed the benefits expanded access to genetic testing for patients with Parkinson disease would bring to the research setting.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 13, 2020.

The chief scientific officer of the Parkinson’s Foundation discussed what has previously been observed in genetic Parkinson disease and what gaps the PD GENEration initiative may fill.

Only small, nonsignificant improvements were observed in Unified Parkinson’s Disease Rating Scale motor scores, though the investigators did not report disease worsening with early treatment.

Researchers developed the biomarker in hopes of simplifying the recent MRPI 2.0 measurement for use in clinical practice.

The chief scientific officer of the Parkinson’s Foundation discussed how the PD GENEration initiative tackles 1 of the greatest unmet needs for patients with Parkinson disease.

The Cleveland Clinic researcher discussed the unknowns about Parkinson disease dementia and what has been previously observed in clinical studies.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending November 7, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Indu Subramanian, MD.

The chief scientific officer at the Parkinson’s Foundation discussed PD GENEration, an initiative to provide genetic testing for patients with Parkinson disease.

Findings from PD GENEration will contribute to the biological understanding of the disease and help researchers assess the impact of each mutation.

The director of the Montefiore Einstein Center for the Aging Brain discussed the details of his study that will evaluate motoric cognitive risk syndrome.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 30, 2020.

The company is planning a pivotal trial of blarcamesine in Parkinson disease dementia after submitting results of the phase 2 study to the FDA for regulatory guidance.

Kristina Simonyan, MD, PhD, DrMed, and Davide Valeriani, PhD, discussed the translational potential of DystoniaNet, and its potential to be adjusted for use in additional disease states.